The “watch and wait” approach is characterized by close surveillance without surgery in patients with rectal cancer who achieve a clinical CR following neoadjuvant CRT.
Suspected local disease regrowth was seen in 23% of patients with rectal cancer observed following a near or complete clinical response to neoadjuvant therapy.
Get the latest treatment options for rectal cancer, including concurrent chemotherapy and radiotherapy and levoleucovorin plus 5-FU.
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
The median number of prior treatments for patients with relapsed colorectal cancer enrolled in this phase 2 study was 6.
The companion study arms under the COLOMATE trial umbrella will include those that specifically enroll patients with HER2-amplified or EGFR-mutant disease.
Participant characteristics were similar between surgical treatment groups.
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.
